Yavuz Goknur Ozaydın, Yılgör Abdullah, Yavuz Ibrahim Halil, Milanlıoğlu Aysel, Çilingir Vedat, Çağaç Aydın, Ozturk Murat, Bilgili Serap Gunes
Department of Dermatology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.
Department of Neurology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.
Postepy Dermatol Alergol. 2019 Apr;36(2):211-216. doi: 10.5114/ada.2018.74834. Epub 2018 Apr 3.
Peripheral neuropathy (PN) is a common neurological condition causing symmetrical and diffuse damage in nerves. The etiology of PN includes systemic diseases, toxic exposure, medications, infections, and hereditary diseases. Omalizumab is a humanized monoclonal anti-IgE antibody that exerts its activity by binding to free IgE in circulation.
To investigate the relationship between omalizumab and peripheral neuropathy.
The study included 30 patients who underwent omalizumab therapy (Xolair) due to the diagnosis of chronic urticaria. A detailed neurological and physical examination was performed in each patient both before and 3 months after the therapy. Electrophysiological examination was also performed using a Medelec Synergy instrument.
The 30 patients included 8 (26.7%) men and 22 (73.3%) women with a mean age of 37.5 ±14.14 years. No serious side effect of the medication was detected in any patient although local wound irritation occurred in 3 (10%) patients. Moreover, no change occurred in the pre-treatment Neuropathy Symptom Score (NSS) or Neurological Disability Score (NDS) of the patients and no pathological values that could result in neuropathy were observed during motor/sensory nerve conduction. However, significant changes were detected in the sensory and motor components of the nerves with regards to pre- and post-treatment values.
Omalizumab therapy caused no peripheral neuropathy in any of our patients but altered the latency, amplitude, and velocity values of the peripheral nerves.
周围神经病变（PN）是一种常见的神经系统疾病，可导致神经出现对称性和弥漫性损伤。PN的病因包括全身性疾病、接触毒物、药物、感染和遗传性疾病。奥马珠单抗是一种人源化单克隆抗IgE抗体，通过与循环中的游离IgE结合发挥作用。
研究奥马珠单抗与周围神经病变之间的关系。
该研究纳入了30例因诊断为慢性荨麻疹而接受奥马珠单抗（Xolair）治疗的患者。在治疗前和治疗后3个月，对每位患者进行了详细的神经学和体格检查。还使用Medelec Synergy仪器进行了电生理检查。
30例患者中，男性8例（26.7%），女性22例（73.3%），平均年龄为37.5±14.14岁。尽管3例（10%）患者出现局部伤口刺激，但未在任何患者中检测到该药物的严重副作用。此外，患者治疗前的神经病变症状评分（NSS）或神经功能障碍评分（NDS）没有变化，在运动/感觉神经传导过程中也未观察到可导致神经病变的病理值。然而，在神经的感觉和运动成分方面，治疗前后的值有显著变化。
在我们的任何患者中，奥马珠单抗治疗均未引起周围神经病变，但改变了周围神经的潜伏期、波幅和速度值。
